Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Fixed-combination drug beneficial in glaucoma therapy
The fixed combination of timolol-dorzolamide (Cosopt, Merck) can be beneficial in glaucoma therapy for several reasons: prescribed in conjunction with a single agent such as a prostaglandin analog, it may achieve a greater reduction in the patient's IOP than the single agent alone, and it can improve compliance, according to two glaucoma experts.
Related Videos
Related Content
